Last updated: 2026-09-04 13:09:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Zentalis Pharmaceuticals, Inc. (ZNTL) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $4.24, with a market capitalization of $356.91M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.21 to $6.95. This page covers its latest market performance, valuation, price trends and company information.
$356.91M | |
$4.05 | |
$87.19 | |
$1.01 | |
$4.11 | |
4.86K | |
-- | |
-- | |
$6.95 | |
$1.21 | |
-- | |
-- |
Zentalis Pharmaceuticals, Inc. (ZNTL) last closed at $4.11 as of 2026-09-04 13:06:00, unchanged from the previous close of $4.11.
During the latest regular trading session, ZNTL traded between $1.01 and $87.19, with a volume of 4.86K shares. The closing price was near the lower end and near the middle of its 52-week range.
Over the past seven days, Zentalis Pharmaceuticals, Inc. (ZNTL) moved from $3.79 to $4.24, representing a gain of 11.93% ($0.45).
The stock traded between $3.55 and $4.42 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 675.77 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 52.8%
ZNTL is currently trading at $4.24, placing it 52.8% of the way from its 52-week low of $1.21 to its 52-week high of $6.95. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 106 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Zentalis Pharmaceuticals, Inc. (ZNTL) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.